A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: A randomized, open-labeled clinical trial

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 7, 2006, Pages 1271-1276

  Yazicioglu, Bengi ^a   Akkaya, Cengiz ^a   Sarandol, Asli ^a   Akgoz, Semra ^a   Saygin Eker, S ^a   Kirli, Selcuk ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Depression; Reboxetine; Sertraline; Venlafaxine

Indexed keywords

REBOXETINE; SERTRALINE; VENLAFAXINE;

ADULT; AGED; AGITATION; ANORGASMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; FLUSHING; FOLLOW UP; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME; XEROSTOMIA;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DRUG EVALUATION; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TIME FACTORS;

EID: 33747067089     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.04.018     Document Type: Article

References (43)

1. Abdelmawla A.H., Langley R.W., Szabadi E., and Bradshaw C.M. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline and methoxamine-evoked constriction of the dorsal hand vein. Br J Clin Pharmacol 48 (1999) 345-354
2. Aguglia E., Casacchia M., Cassano G.B., Faravelli C., Ferrari G., Giordano P., et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 8 (1993) 197-202
3. Akdemir A., Orsel S.D., Dag I., Turkcapar M.H., Iscan N., and Ozbay H. Hamilton Depresyon Derecelendirme Olcegi (HDDO)'nin gecerligi-guvenirligi ve klinikte kullanimi (Validity-reliability and clinical use of Turkish version of Hamilton depression rating scale). Psikiyatri Psikol Psikofarmakol Derg (3P) 4 (1996) 251-259
4. Akkaya C., Sivrioglu Y., Sarandol A., and Kirli S. Major depresif bozukluk'ta venlafaksin XR ve reboksetin'in etkililik ve guvenilirliginin karsilastirilmasi (Comparison of venlafaxine XR and reboxetine in terms of efficacy and safety in Major Depressive Disorder). Yeni Symp 41 (2003) 170-177
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Association, Washington DC
6. Amsterdam J.D., Garcia-Espana F., and Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety 5 (1997) 84-90
7. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58 (2000) 19-36
8. Baca E., Gonzalez de Chavez M., Garcia-Toro M., Perez-Arnau F., and Porras-Chavarino A. Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 493-500
9. Carpenter L.L., Yasmin S., and Price L.H. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51 (2002) 183-188
10. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 90 (1986) 131-138
11. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 18 (1990) 289-299
12. DeBattista C., Solvason H.B., Poirier J., Kendrick E., and Schatzberg A.F. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol 23 (2003) 27-30
13. Declaration of Helsinki. World Medical Organization. Br Med J 313 (1996) 1448-1449
14. Devarajan S., and Dursun S.M. Citalopram plus reboxetine in treatment-resistant depression. Can J Psychiatry 45 (2000) 489-490
15. Dursun S.M., and Devarajan S. Reboxetine plus citalopram for refractory depression not responding to venlafaxine: possible mechanisms. Psychopharmacology (Berl) 153 (2001) 497-498
16. Faravelli C., Cosci F., Ciampelli M., Scarpato M.A., Spiti R., and Ricca V. A self-controlled, naturalistic study of selective serotonin reuptake inhibitors versus tricyclic antidepressants. Psychother Psychosom 72 (2003) 95-101
17. Fava M., and Davidson K.G. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19 (1996) 179-200
18. Fava M., McGrath P.J., and Sheu W.P. Reboxetine study group.switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol 23 (2003) 365-369
19. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48 (1991) 851-855
20. Guelfi J.D., White C., Hackett D., Guichoux J.Y., and Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 56 (1995) 450-458
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised US Dept Health, Education and Welfare publication (ADM) (1976), National Institute of Mental Health, Rockville, Md. 76-338
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 23 (1960) 56-62
23. Judd L.L., Akiskal H.S., and Paulus M.P. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord 45 (1997) 5-18
24. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50 (1998) 97-108
25. Kaplan E.M. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther 24 (2002) 1194-1200
26. Kennedy S.H., McCann S.M., Masellis M., McIntyre R.S., Raskin J., McKay G., et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 63 (2002) 181-186
27. Khan A., Fabre L.F., and Rudolph R. Venlafaxine in depressed out patients. Psychopharmacol Bull 27 (1991) 141-144
28. Kirli S. Depresyonun biyolojik olusumu ve farmakolojik tedavisi (Biological mechanism of depression and its treatment) (2000), F. Özsan Matbaaci{dotless}li{dotless}k, Bursa
29. Mehtonen O.P., Sogaard J., Roponen P., and Behnke K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 study group. J Clin Psychiatry 61 (2000) 95-100
30. Mitchell P.B., Schweitzer I., Burrows G., Johnson G., and Polonowita A. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol 20 (2000) 483-487
31. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatr 134 (1979) 382-389
32. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 11 Suppl 4 (1997) S33-S37
33. Nierenberg A.A., and Wright E.C. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 60 Suppl 22 (1999) S7-S11
34. Nierenberg A.A., Feighner J.P., Rudolph R., Cole J.O., and Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 14 (1994) 419-423
35. Nierenberg A.A., Susman N., and Trivedi M.H. Managing relapse in depression, choice of antidepressants for major depressive disorder (2003), Science Press Ltd., London
36. Racagni G., and Brunello N. Physiology to functionality: the brain and neurotransmitter activity. Int Clin Psychopharmacol 14 Suppl 1 (1999) S3-S7
37. Roose S.P., Glassman A.H., Attia E., and Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 151 (1994) 1735-1739
38. Rubio G., San L., Lopez-Munoz F., and Alamo C. Reboxetine adjunct for partial or nonresponders to antidepressant. J Affect Disord 81 (2004) 67-72
39. Saiz-Ruiz J., Ibanez A., Diaz-Marsa M., Arias F., Padin J., and Martin-Carrasco M. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 1129-1134
40. Schatzberg A.F. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 61 Suppl 10 (2000) S31-S38
41. Tamam L., and Zeren T. Depresyonda serotonerjik duzenekler (Serotonergic system in depression). Klin Psikiyatri Derg 5 (2002) 11-18
42. Torun F., Onder M.E., Torun S.D., Tural U., and Sismanlar S.G. Montgomery-Asberg Depresyon Derecelendirme olcegi Turkce formunun gecerlik ve guvenirligi (Validity-relaibility and clinical use of Turkish version of Montgomery-Asberg depression rating scale). 3P Dergisi 10 (2002) 319-330
43. Versiani M., Amin M., and Chouinard G. Double-blind, placebo-controlled study with reboxetine in in-patients with severe major depressive disorder. J Clin Psychopharmacol 20 (2000) 28-34